Oral treprostinil diethanolamine for pulmonary arterial hypertension

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 55-60

  Feldman, Jeremy ^a   Im, Yunhee ^b   Gill, Kirat ^b  

^a Arizona Pulmonary Specialists   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

oral treprostinil; orenitram; orenitram dosing; PAH treatment; prostanoid; pulmonary arterial hypertension

Indexed keywords

TREPROSTINIL; ANTIHYPERTENSIVE AGENT; DIETHANOLAMINE; ETHANOLAMINE DERIVATIVE; PROSTACYCLIN;

ADD ON THERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; INTENTION TO TREAT ANALYSIS; MONOTHERAPY; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZATION; REVIEW; VOMITING; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HYPERTENSION, PULMONARY; ORAL DRUG ADMINISTRATION; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; EPOPROSTENOL; ETHANOLAMINES; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84916926371     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.984690     Document Type: Review

References (14)

1. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70(4):580-7
2. Falk A, Lookstein RA, Mitty HA. Flolan infusion interruption: a lethal complication during venous access. J Vasc Interv Radiol 2001;12:5-667-8
3. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from the time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest J 2012;142(2):448-56
4. Barst RJ, Rubin LJ, Walker A, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334(5): 296-301
5. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest J 2012;142(6):1383-90
6. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4
7. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study) treprostinil for pulmonary arterial hypertension a randomized controlled trial. Chest J 2013;144(3):952-8
8. Jing ZC, Parikh P, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial. Circulation 2013;127(5):624-33
9. White J, Chakinala MM, Mathier M, et al. Safety and tolerability of transitioning from parenteral treprostinil to oral treprostinil in patient with PAH. American Thoracic Society 2014 International Conference Oral Presentation, San Diego, Pulm Circ 2013 Jan. 3(1):116-20
10. United Therapeutics. Trial of the early combination of oral treprostinil with a PDE-5 inhibitor or ERA in subjects with pulmonary arterial hypertension (FREEDOM-EV). In: ClinicalTrials.gov [Internet] Bethesda (MD):National Library of Medicine (US), 2000.[cited 14 August 2014] Available from: http://clinicaltrial. gov/ct2/show/NCT01560624 NLM Identifier: NCT: 01560624
11. Orenitram. package insert United Therapeutics Corp. Triangle Park, NC;2013
12. Selexipag. Actelion Pharmaceuticals Ltd. 22 July 2014. Available from: www.actelion. com/sites/en/scientists/development-pipeline/ phase-3/selexipag.page. [Last accessed 16 August 2014]
13. Hoeper MM, Barst RJ, Feldman J, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRESS study. Circulation 2013;127(10):1128-38
14. AMBITION Top line results, gilead sciences. [8 August 2014]. Press Release.